Patents by Inventor Gregory Hinkle

Gregory Hinkle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HEPATITIS B VIRUS (HBV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20200140864
    Abstract: The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the hepatitis B virus (HBV) genome, and methods of using such RNAi agents to inhibit expression of one or more HBV genes and methods of treating subjects having an HBV infection and/or HBV-associated disorder, e.g., chronic hepatitis B infection.
    Type: Application
    Filed: November 4, 2019
    Publication date: May 7, 2020
    Inventors: Gregory Hinkle, Laura Sepp-Lorenzino, Vasant Jadhav, Martin Maier, Stuart Milstein, Muthiah Manoharan, Kallanthottathil G. Rajeev
  • Hepatitis D virus (HDV) iRNA compositions and methods of use thereof
    Patent number: 10640770
    Abstract: The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the hepatitis D virus (HDV) genome, and methods of using such RNAi agents to inhibit expression of one or more HBV genes and methods of treating subjects having an HDV infection and/or HDV-associated disorder.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: May 5, 2020
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Gregory Hinkle, Laura Sepp-Lorenzino, Vasant Jadhav, Martin Maier, Muthiah Manoharan, Stuart Milstein, Svetlana Shulga Morskaya, Kallanthottathil G. Rajeev, Huilei Xu
  • FACTOR XII (HAGEMAN FACTOR) (F12), KALLIKREIN B, PLASMA (FLETCHER FACTOR) 1 (KLKB1), AND KININOGEN 1 (KNG1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20200131513
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Kallikrein B, Plasma (Fletcher Factor) 1 (KLKB1) gene, the Factor XII (Hageman Factor (F12) gene, or the Kininogen 1 (KNG1) gene, and methods of using such RNAi agents to inhibit expression of a KLKB1 gene, an F12 gene, and/or a KNG1 gene, and methods of treating subjects having an hereditary angioedema (HAE) and/or a contact activation pathway-associated disorder.
    Type: Application
    Filed: May 24, 2019
    Publication date: April 30, 2020
    Applicant: Alnylam Pharmaceuticals, Inc.
    Inventors: Akin Akinc, Gregory Hinkle, Martin A. Maier, James Butler, Jingxuan Liu
  • LACTATE DEHYDROGENASE A (LDHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20200113927
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the LDHA gene, as well as methods of inhibiting epression of LDHA, methods of inhibiting LDHA and HAO1, and methods of treating subjects that would benefit from reduction in expression of LDHA, such as subjects having an oxalate pathway-associated disease, disorder, or condition, using such dsRNA compositions.
    Type: Application
    Filed: December 17, 2019
    Publication date: April 16, 2020
    Inventors: David Erbe, Abigail Liebow, Kevin Fitzgerald, Gregory Hinkle, Kyle David Wood, Ross Philip Holmes, John Knight
  • POLYNUCLEOTIDE AGENTS TARGETING SERPINC1 (AT3) AND METHODS OF USE THEREOF
    Publication number: 20200102560
    Abstract: The invention relates to polynucleotide agents targeting the Serpinc1 (AT3) gene, and methods of using such polynucleotide agents to inhibit expression of Serpinc1 and to treat subjects having a bleeding disorder, e.g., a hemophilia.
    Type: Application
    Filed: May 13, 2019
    Publication date: April 2, 2020
    Inventor: Gregory Hinkle
  • POLYNUCLEOTIDE AGENTS TARGETING COMPLEMENT COMPONENT C5 AND METHODS OF USE THEREOF
    Publication number: 20200095578
    Abstract: The invention relates to polynucleotide agents targeting the complement component C5 gene, and methods of using such polynucleotide agents to inhibit expression of C5 and to treat subjects having a complement component C5-associated disease, e.g., paroxysmal nocturnal hemoglobinuria.
    Type: Application
    Filed: July 2, 2019
    Publication date: March 26, 2020
    Inventor: Gregory Hinkle
  • Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (PNPLA3) and methods of use thereof
    Patent number: 10597661
    Abstract: The invention relates to polynucleotide agents targeting a Patatin-Like Phospholipase Domain Containing 3 (PNPLA3) gene, and methods of using such polynucleotide agents to inhibit expression of a PNPLA3 gene and methods of treating subjects having Nonalcoholic Fatty Liver Disease (NAFLD) and/or a PNPLA3-associated disorder.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: March 24, 2020
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventor: Gregory Hinkle
  • SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20200080085
    Abstract: The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the Serpina1 gene, and methods of using such RNAi agents to inhibit expression of Serpina1 and methods of treating subjects having a Serpina1 associated disease, such as a liver disorder.
    Type: Application
    Filed: November 11, 2019
    Publication date: March 12, 2020
    Inventors: Alfica Sehgal, Klaus Charisse, Brian Bettencourt, Martin A. Maier, Kallanthottathil G. Rajeev, Gregory Hinkle, Muthiah Manoharan
  • APOLIPOPROTEIN C3 (APOC3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20200080088
    Abstract: The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the apolipoprotein C3 (APOC3) gene, and methods of using such RNAi agents to inhibit expression of APOC3 and methods of treating subjects having an APOC3 associated disorder, e.g., hypertriglyceridemia.
    Type: Application
    Filed: November 25, 2019
    Publication date: March 12, 2020
    Inventors: Kevin Fitzgerald, William Querbes, James Butler, Stephanie Williams, Abigail Liebow, Gregory Hinkle, Martin A. Maier, Stuart Milstein, Satyanarayana Kuchimanchi, Muthiah Manoharan
  • Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
    Patent number: 10570393
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ANGPTL3 gene, as well as methods of inhibiting expression of ANGPTL3 and methods of treating subjects having a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia, using such dsRNA compositions.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: February 25, 2020
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: William Querbes, Kevin Fitzgerald, James Butler, Stephanie Williams, Gregory Hinkle, Martin Maier
  • Organic compositions to treat beta-ENaC-related diseases
    Patent number: 10550391
    Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: February 4, 2020
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: Antonin De Fougerolles, John Diener, Emma Hickman, Gregory Hinkle, Stuart Milstein, Anne-Marie Pulichino, Andrew Griffin Sprague
  • Hepatitis B virus (HBV) iRNA compositions and methods of use thereof
    Patent number: 10513703
    Abstract: The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the hepatitis B virus (HBV) genome, and methods of using such RNAi agents to inhibit expression of one or more HBV genes and methods of treating subjects having an HBV infection and/or HBV-associated disorder, e.g., chronic hepatitis B infection.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: December 24, 2019
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Gregory Hinkle, Laura Sepp-Lorenzino, Vasant Jadhav, Martin Maier, Stuart Milstein, Muthiah Manoharan, Kallanthottathil G. Rajeev
  • Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
    Patent number: 10494632
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the insulin-like growth factor binding protein, acid labile subunit (IGFALS) gene or the insulin-like growth factor 1 (IGF-1) gene, methods of using such double stranded RNAi agents to inhibit expression of an IGFALS gene or an IGF-1 gene, and methods of treating subjects having an IGF system-associated disorder.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: December 3, 2019
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: James Butler, Kevin Fitzgerald, Gregory Hinkle, Brian Bettencourt, Huilei Xu
  • Lipid formulated compositions and methods for inhibiting expression of Serum Amyloid A gene
    Patent number: 10472628
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a Serum Amyloid A (SAA) gene, and methods of using the dsRNA to inhibit expression of SAA.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: November 12, 2019
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Antonin de Fougerolles, Tatiana Novobrantseva, Gregory Hinkle
  • Compositions and Methods for Inhibiting Expression of Transthyretin
    Publication number: 20190309293
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a transthyretin (TTR) gene, and methods of using the dsRNA to inhibit expression of TTR.
    Type: Application
    Filed: February 14, 2019
    Publication date: October 10, 2019
    Inventors: Dinah Wen-Yee Sah, Gregory Hinkle, Rene Alvarez, Stuart Milstein, Qingmin Chen
  • ANGIOTENSINOGEN (AGT) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20190298842
    Abstract: The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the angiotensinogen (AGT) gene, and methods of using such RNAi agents to inhibit expression of AGT and methods of treating subjects having an AGT-associated disorder, e.g., hypertension.
    Type: Application
    Filed: February 13, 2019
    Publication date: October 3, 2019
    Inventors: Donald Foster, Brian Bettencourt, Klaus Charisse, Gregory Hinkle, Satyanarayana Kuchimanchi, Martin A. Maier, Stuart Milstein
  • ORGANIC COMPOSITIONS TO TREAT HSF1-RELATED DISEASES
    Publication number: 20190276827
    Abstract: The present disclosure relates to methods of treating heat shock factor 1 (HSF1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a RNAi agent to HSF.
    Type: Application
    Filed: May 14, 2019
    Publication date: September 12, 2019
    Inventors: Gregory Hinkle, Satyanarayana Kuchimanchi, Stuart Milstein, Markus Warmuth, Wenlai Zhou, Ping Zhu, Tracy S. Zimmermann
  • Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
    Patent number: 10407679
    Abstract: The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the apolipoprotein C3 (APOC3) gene, and methods of using such RNAi agents to inhibit expression of APOC3 and methods of treating subjects having an APOC3 associated disorder, e.g., hypertriglyceridemia.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: September 10, 2019
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Kevin Fitzgerald, William Querbes, James Butler, Stephanie Williams, Abigail Liebow, Gregory Hinkle, Martin Maier, Stuart Milstein, Satyanarayana Kuchimanchi, Muthiah Manoharan
  • Polynucleotide agents targeting complement component C5 and methods of use thereof
    Patent number: 10400238
    Abstract: The invention relates to polynucleotide agents targeting the complement component C5 gene, and methods of using such polynucleotide agents to inhibit expression of C5 and to treat subjects having a complement component C5-associated disease, e.g., paroxysmal nocturnal hemoglobinuria.
    Type: Grant
    Filed: March 6, 2017
    Date of Patent: September 3, 2019
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventor: Gregory Hinkle
  • Ketohexokinase (KHK) iRNA compositions and methods of use thereof
    Patent number: 10370666
    Abstract: The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the ketohexokinase (KHK) gene, and methods of using such RNAi agents to inhibit expression of KHK and methods of treating subjects having a KHK-associated disorder, e.g., liver disease (e.g., fatty liver, steatohepatitis), dyslipidemia (e.g., hyperlipidemia, high LDL cholesterol, low HDL cholesterol, hypertriglyceridemia, postprandial hypertriglyceridemia), disorders of glycemic control (e.g., insulin resistance, diabetes), cardiovascular disease (e.g., hypertension, endothelial cell dysfunction), kidney disease (e.g., acute kidney disorder, tubular dysfunction, proinflammatory changes to the proximal tubules), metabolic syndrome, adipocyte dysfunction, visceral adipose deposition, obesity, hyperuricemia, gout, eating disorders, and excessive sugar craving.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: August 6, 2019
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Kevin Fitzgerald, Brian Bettencourt, Gregory Hinkle, Jennifer Willoughby